Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million

Reuters

Nov 26, 2025

<a href="https://laohu8.com/S/CLGN">Collplant Biotechnologies</a> 9M 2025 net loss narrows 35% to USD 8.3 million

CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2586425493"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586425493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586425493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586425493","market":"fut","top_or_hot":-1,"title":"Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> 9M 2025 net loss narrows 35% to USD 8.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-26 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> 9M 2025 net loss narrows 35% to USD 8.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLGN","symbol_name":"COLLPLANT BIOTECHNOLOGIES LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL9Mq4C:1","article_id":"2586425493","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586425493","pubTimestamp":1764160231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CollPlant Biotechnologies Ltd. reported results for the third quarter  and nine months  ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLGN":"COLLPLANT BIOTECHNOLOGIES LTD","BK4139":"生物科技"},"translate_title":"Collplant Biotechnologies 9M 2025年净亏损收窄35%至830万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLGN":0.9},"content_text":"Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million\n    \n\n        CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}